The specter of generic challenges has repeatedly loomed above copyright’s blockbuster drug, Viagra, raising questions about the prospects of related drug investments. While early periods saw significant gains, the intellectual property lapse has created the door for discounted alternatives, possibly diminishing profitability and creating a genuin